Introduction
Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer worldwide, with a global annual incidence of 780,000 new cases (1) . More than 90% of these cancer types have a squamous origin, and common sites include the hypopharynx, larynx, oral cavity, nasopharynx, oropharynx, paranasal sinus, nasal cavity, parathyroid and salivary glands (2, 3) . Laryngeal squamous cell carcinoma is a very common type of head and neck cancer, corresponding to ~25% of HNSCC cases (4) . Tobacco and/or alcohol consumption are the two main risk factors involved in the development of HNSCC. Other risk factors include poor oral hygiene, nutritional deficiencies and certain viruses, such as human papilloma (HPV) and Epstein-Barr (2, 5, 6) .
Despite advances in treatment, the long-term survival rate of patients with head and neck squamous cell carcinoma has remained at 50%, with high rates of associated mortality (5) . Late presentation of the lesion, lack of suitable markers for early detection and failure of advanced lesions to respond to the available chemotherapy contribute to a poor outcome of HNSCC (7) . However, loco-regional relapse and metastasis after conventional therapy appear to be significant contributing factors for restricted survival of HNSCC patients (1) .
The development of HNSCC is a multistep process accompanied by genetic and epigenetic changes, including loss of heterozygosity (LOH), gene inactivation by methylation and gene amplification, which can alter gene expression (8) . Various studies have revealed numerous molecular abnormalities in HNSCC, including activation of oncogenes such as CCND1 (9) , EGFR (10), RAS (11) and C-MYC (12); inactivation of tumor suppressor genes such as CDKN2A (p16) (13) , TP53 (14) , p27 (15) and WAF1/C1P1 (16) ; expression of angiogenic factors and LOH at numerous chromosomal locations (17, 18) . For instance, the most frequent cytogenetic alterations in HNSCC are gains of 3q, 8q, 20q, 7q, 11q13 and 5p, and losses in 3p, 9p, 21q, 5q, 13q, 18q and 8p (19) . The involved loci correspond to genes that encode specific functional classes of proteins, such as cell cycle regulators, tumor suppressors, cell adhesion and protein kinases (20) . However, the complete array of molecular changes that occur during oncogenesis and HNSCC progression remains elusive.
Large-scale studies involving microarrays have identified specific gene expression signatures associated with expression changes in HNSCC tissue samples compared to normal tissue, as well as genes involved in clinical outcome and metastasis (19, 21, 22) . However, most microarray studies were performed using tumors from different sites in head and neck.
In the present study, we constructed a cDNA microarray platform containing probes for 284 genes previously identified by the Head and Neck Annotation Consortium (23) , and used these arrays to search for genes differentially expressed in clinical samples from squamous cell carcinoma of the larynx. The genes included in the array are candidates for LOH or gene amplification in head and neck tumors identified following an informatics analysis of EST libraries derived from non-tumor and tumor tissues of the oral cavity, larynx, pharynx and thyroid (23) . However, their differential expression in malignant and non-tumor head and neck tissues has yet to be evaluated. By analyzing only larynx carcinoma samples, we aimed to minimize the genetic differences that may be present in anatomically diverse tumors of the head and neck region, thus favoring the identification of genes associated with tumors with the same histological origin.
We observed a significant increase or decrease in the mRNA levels of 35 genes in larynx tumor samples. These genes are involved in processes such as cell cycle, apoptosis, DNA repair, protease inhibition, proteolysis and transcriptional regulation. Our findings contribute to the understanding of the molecular basis of larynx cancer and provide a set of genes that may be useful for the development of novel diagnostic markers and/or more effective therapeutic strategies.
Materials and methods
cDNA microarray construction. We selected 135 genes previously identified by the Head and Neck Annotation Consortium (23) to be spotted into a custom-built cDNA microarray. These included genes that map to loss or gain regions involved in head and neck carcinogenesis, according to Knuutila et al (24) .
Complementary DNA of the human laryngeal carcinoma (Hep2) cell line served as a template for the amplification of probes from microarray spotting. Gene-specific primers for PCR were designed using the Primer 3.0 program (25) to amplify fragments with an average size of 600 bp. In brief, for the PCR, 1 μl cDNA was mixed with 2.5 μl 10X buffer, 1 μl PCR primer (10 pmol/μl), 4 μl dNTPs (1.25 mM), 0.75 μl MgCl 2 (50 mM) and 0.2 μl Taq DNA platinum (Invitrogen). PCR conditions were: 94˚C for 4 min, followed by 35 cycles at 94˚C for 30 sec, 60˚C for 1 min and 72˚C for 1 min.
From the products obtained, 5 μl were fractionated by electrophoresis through a 1% agarose gel for size verification, and the remaining 95 μl were purified by filtration on Multiscreen plates (Millipore cat. # MAFB NOB 50). cDNA samples were diluted 1:1 in DMSO and spotted onto silanecoated, reflective Type-7 glass slides (Molecular Dynamics), using a GenIII microarray spotter robot (Molecular Dynamics). Twelve replicates of 4 different plant/bacterial DNA fragments with no similarity to human sequences were evenly distributed along the slide to serve as negative controls of non-specific hybridization (Lucidea ScoreCard, GE Healthcare). Following spotting, cDNAs were fixed to the slide surface by UV cross-linking (500 mJ) and kept in a low-humidity environment until use.
Based on an informatics analysis of the head and neck (HN) transcriptome to identify candidates for LOH in HN tumors (23) , an additional set of 196 cDNA clones were included in the array, comprising partial sequences of proteincoding transcripts (123 sequences), as well as of transcripts mapping to intronic (53 sequences) or intergenic regions of the genome (20 sequences). The original sequencing clone collection was stored frozen in bar-coded 96-well plates, and the selected clones were re-arrayed in an automated robotic operation. cDNA fragments were generated from these clones by PCR amplification with universal primers, purified by filtration and spotted as described above.
Each sequence was spotted in 6-replicates in the microarrays. The complete list of the 331 cDNA clones deposited in the head and neck cancer cDNA platform are deposited in the Gene Expression Omnibus (GEO) database (http:// www.ncbi.nlm.nih.gov/geo/) under the accession number GPL6426.
Patient samples. This study was approved by the Brazilian National Research Ethics Committee and written informed consent was obtained from the participating individuals prior to sample collection. A total of 15 larynx tumor samples and 10 non-matched, histologically normal adjacent larynx tissue samples were obtained at the time of surgery from the Arnaldo Vieira de Carvalho Hospital. They were immediately snap-frozen in liquid nitrogen.
Medical records were examined to obtain clinical and histopathological information for each patient, including age, gender, histopathological diagnosis, as well as history of tobacco and alcohol consumption. Tumors were staged according to the current TNM classification, as recommended by the UICC (26) . Patient clinical data and tumor characteristics are described in Table I. Prior to RNA extraction, samples were re-examined, and Giemsa-stained microsections obtained from each side of the frozen block were used to delimit the spatial distribution of the tumor mass or non-tumor tissue. Microdissections were performed to ensure that >70% of the isolated RNA was derived from cancer cells. In the case of surgical margins, only the epithelial tissue was used. Microdissected tumor and non-tumor samples were returned to liquid nitrogen until use.
RNA extraction. Snap-frozen tissue samples were pulverized using a mortar pestle. Total RNA was isolated from tissue specimens and Hep2 cell culture using TRIzol reagent (Gibco BRL, Life Technologies). Total RNA was precipitated by incubating with 0.5 ml of isopropyl alcohol for 10 min, followed by centrifugation at 12,000 x g for 10 min at 4˚C. The pellet was washed with 75% ethanol, solved in RNAse-free water, passed through an RNeasy spin column (Qiagen) for purification and stored at -80˚C until further use. Table I. Patient clinical and anatomopathological data.  -----------------------------------------------------------------------------------------------------TNM RNA quantity and quality were evaluated using a spectrophotometer, 1% agarose gel electrophoresis and microelectrophoresis on a Bioanalyzer 2100 (Agilent Technologies). RNA from the samples was of appropriately high quality for cDNA microarray analysis.
Probe labeling and hybridization. The experimental design employed a one-color approach to obtain gene expression measurements (27) . Labeled targets for hybridizations were generated from total mRNA in reverse transcription reactions using oligo-dT primers, following the protocol accompanying the CyScribe First-Strand labeling kit strictly (Amersham Biosciences, Piscataway, NJ). Total RNA (15 μg) from each sample was mixed with 4 μl anchored oligo (dT) (500 μg/ml), in a total volume of 11 μl, denatured at 70˚C for 5 min, put on ice for 30 sec, spun down and placed at room temperature for 10 min. Then, 1 μl of dNTP mix, 1 μl of aminoallyl-dUTP, 2 μl of 0.1 M DTT, 1 μl of RNaseOUT (40 U/μl), 4 μl of 5X CyScript buffer and 1 μl of CyScript reverse transcriptase (200 U/μl) were added. The volume was adjusted to 20 μl with water. After incubation for 3 h at 42˚C, RNA was hydrolyzed by adding 2 μl of 2.5 N NaOH for 15 min at 37˚C. Samples were then neutralized with 10 μl of 2 M HEPESfree acid, and reactions were purified using 96-well Millipore multiscreen filter plates as follows: 5 volumes of 5.3 M guanidine-HCl and 150 mM KOAc were added to labeling reactions. The mixture was applied onto the plate and washed 4 times with 80% EtOH by centrifugation at 3500 rpm for 5 min. Residual ethanol was spun out by an additional centrifugation at 3500 rpm for 5 min. Labeled targets were eluted in 50 μl 10 mM Tris pH 8.5, by spinning at 3000 rpm for 5 min, dried on a SpeedVac and kept at -20˚C, protected from light until use. cDNA was re-suspended in 40 μl of 0.1 M NaHCO 3 and reacted with monoreactive NHS-ester Cy5 dye. The reaction was incubated for 2 h at room temperature and purified.
Labeled targets were re-suspended in 250 μl of 1X hybridization buffer [25% formamide, 12.5% of proprietary Microarray Hybridization Buffer Version 2 (Amersham Biosciences)], denatured for 2 min at 92˚C and centrifuged at 13,000 rpm for 5 min. The Cy5-(tumor or non-tumor sample) labeled cDNAs were incubated individually with microarrays using an Automated Slide Processor (ASP, GE Healthcare) for 16 h at 42˚C. Following hybridization, slides were washed (1.0X SSC, 0.2% SDS for 10 min at 55˚C; 0.1X SSC, 0.2% SDS for 10 min at 55˚C; 0.1X SSC, 0.2% SDS for 10 min at 55˚C; 0.1X SSC for 1 min at RT; 0.1X SSC for 1 min at RT and dH 2 O for 10 sec at RT), and dried with a N2 stream.
Data measurement and normalization. Processed slides were scanned with a 700 V PMT setting (GenIII scanner, Amersham Biosciences), and background-subtracted artifactremoved median intensities of Cy5 emissions were extracted for each spot from raw images, using the ArrayVision V.7.2 software (Imaging Research Inc., Ontario, Canada). An array grid was automatically aligned to locate the position of each spot in the array, and then manually adjusted to obtain the best possible alignment.
To make the experiments comparable, intensity data from each hybridized test sample was normalized by Local weighted scatter-plot smoothing LOWESS (28) . Intensity data from a sample with total energy comparable to the average intensity of the samples was used as a reference in the LOWESS normalization procedure. Raw and normalized microarray intensities are deposited in the GEO database (http://www.ncbi.nlm.nih.gov/geo/) under the accession number GSE10288.
Statistical analysis of microarray data. To identify genes with a significantly altered expression in larynx tumors, a signalto-noise ratio (SNR) metric (29) was used to compare the expression intensity data from tumor and non-tumor samples. The SNR parameter is essentially a measure of signal strength relative to background noise. The distance between the two groups was measured by a signal (expression intensity) to noise (variation) ratio. The signal-to-noise comparison gives an indication of the level of separation for the means of the two distributions defining the gene intensities of the two groups, and was calculated as:
where X 1 and X 2 , respectively, are the mean intensities of tumor and non-tumor groups, and S 1 and S 2 , respectively, the corresponding standard deviations. For each gene, higher absolute SNR values indicate a greater difference of expression between tumor and non-tumor samples, with a lower dispersion within each group. A cut-off SNR ≥ | 1 |, p≤0.001 was used to select differentially expressed genes. Statistical significance of the differential expression (p-values) was ascertained by bootstrap re-sampling, i.e., by re-calculating SNR values following 10,000 random permutations of sample labels and computing the frequency at which each SNR value measured in the original set was observed in the randomly permuted data (29) . Expression profiles of selected transcripts were grouped using hierarchical clustering (UPGMA with Euclidean distance) and visualized using the computer software Spotfire Decision Site (Spotfire, Somerville, MA, USA).
Real-time RT-PCR experiments and statistical analysis.
For an independent validation of the array data, we selected 14 genes which were down-regulated in tumor tissues as measured by microarray analysis. The cDNA sequence of each gene was selected from the internationally published databases (http://www.ncbi.nlm.ni.gov/) and gene-specific primers for real-time RT-PCR were designed for optimal hybridization kinetics, using the Primer 3.0 program (25) . Amplification primers were designed into different exons, to avoid the amplification of any contaminating genomic DNA. Primer sequences are shown in Table III. For validation, we used total RNA from 15 tumor samples (T1-T15) and a pool of RNA from 7 histologically normal larynx mucosa tissue samples adjacent to tumors, considered here as a normal reference. Double-stranded cDNA was synthesized from total RNA, using high-capacity cDNA archive (Applied Biosystems) according to the manufacturer's instructions.
Real-time PCR was performed using the ABI prism 7300 sequencer detector system and SYBR-Green PCR core reagent (Applied Biosystems) following the manufacturer's protocol. In brief, the reaction mixture (20 μl total volume) contained 25 ng of cDNA, gene-specific forward and reverse primers for each gene at a final concentration of 0.4 or 0.5 μM, and 10 μl of 2X quantitative SYBR-Green PCR master mix. The relative quantification was given by the CT values, determined for triplicate reactions for tumor and reference samples from each gene and for the endogenous control (·-tubulin, TUBA1C). Thus, the fold-change of each gene was calculated by using the 2 -ΔΔCT formula, where CT = fluorescence at the defined detection threshold; ΔCT = CT of the target gene -CT of the endogenous control and ΔΔCT = ΔCT (tumor sample) -ΔCT (reference sample). For the tumor sample, evaluation of 2 -ΔΔCT indicates the fold change in gene expression relative to the reference sample.
Statistical analysis was performed using the Minitab software (version 12.22) and the significance level was defined as ·=0.05. Relative expression levels detected by quantitative real-time RT-PCR for the 14 genes in samples from larynx carcinoma were transformed into natural logarithms. The Anderson-Darling normality test was performed to determine whether or not the values presented a normal distribution. As this test did not reject normality for the 14 genes, data were subjected to a one-sample Student's t-test on their expression levels at the logarithmic scale.
Results
Epidemiology. The study population included 14 males and 1 female with larynx carcinoma. Minimum and maximum ages were 44 and 73 years, respectively, with a mean age of 58.7±9.8 years. Patients at the UICC stage were: 1 T2, 2 T3 and 12 T4, while at the neck stage, there were: 7 N0, 2 N1 and 6 N2 patients. Thus, 93% of the patients had T3-T4 tumors and 60% had regional metastases at presentation. None of the patients had distant metastases upon diagnosis of the disease. Regarding the clinical stage, 3 patients had stage III and 12 had stage IV. Six patients presented no clinical evidence of the disease at the last follow-up, and 9 patients showed disease recurrence. Recurrence occurred between 4 and 14 months after surgery. Our data are in agreement with the literature, since 40-50% of patients with advanced disease (stage III and IV) exhibited recurrence, and ~80% of these recurrences occurred within the first two years. Regarding the risk factors, 100% were smokers and 94% used to consume alcohol. Therefore, most of these patients had a history of smoking and drinking, which are the major etiological factors in larynx cancer. Patient data are presented in Table I .
Gene expression analysis of larynx tumors. Expression analysis using the 331-element cDNA microarray was initially performed on 8 larynx tumor (T1-T8) and 4 larynx non-tumor samples.
Differentially expressed genes were identified using the signal-to-noise ratio (SNR) metric as described in Materials and methods. Of the 285 genes analyzed, 35 (12% of the total) showed statistically significant differences in the expression between tumor and adjacent non-tumor larynx tissue (SNR ≥| 1.0 |, p≤0.001). Among these 35 genes, 19 (54%) showed a higher expression in tumor than in non-tumor tissue, and 16 (46%) presented the contrasting pattern.
Supervised hierarchical clustering analysis revealed that the expression patterns of the selected set of 35 differentially expressed genes were able to perfectly distinguish tumors from non-malignant tissues in the set of samples used in this training set (Fig. 1) . Two subgroups of tumor samples were distinguishable in the training set based on the expression profile of the 35 genes (Fig. 1) , suggesting heterogeneity among larynx cancer cases. Separation of these samples into 2 subgroups does not appear to correlate with the clinical staging or metastatic features of the tumors. In contrast, we observed a statistically significant difference (p=0.030) in the mean age of patients upon disease presentation in each subgroup: in one, the ages of patients ranged between 44 and 58 years (51±5.5), and in the other from 61 to 73 (68±4.7).
To verify the robustness of the 35-gene signature, we investigated whether this gene set was able to distinguish tumor from non-tumor larynx tissues, using data from an additional set of 5 larynx tumor samples (T9, T10, T11, T14 and T15) and 6 additional adjacent non-tumor larynx tissue samples. As shown in Fig. 2 , the 35-gene set was able to separate this additional set of larynx samples according to ONCOLOGY REPORTS 21: 649-663, 2009 Figure 1. Supervised hierarchical clustering of 8 larynx tumor and 4 nontumor samples used in the training set. A total of 35 differentially expressed genes was identified, using a signal-to-noise ratio of >|1| and p≤0.001 as cut-offs. Selected transcripts were grouped using hierarchical clustering (Wards method with half square Euclidean distance), and heat maps were constructed using the Spotfire software. For each gene (row), red indicates a higher expression and green a lower one relative to the average level of expression of that gene across the 35 samples (columns). Table II . The 35 genes showing down-or up-regulation in larynx cancer.
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A functional classification of the selected 35-gene set was performed manually by querying the Entrez Gene database (30) . We observed that these genes are involved in processes such as apoptosis, cell adhesion, cell cycle, cell motility, DNA repair, metabolism, proteolysis, signal transduction and transcriptional regulation (Table II) . Thus, of the 19 genes identified and overexpressed in larynx tumors, 2 were involved in signal transduction, 2 in transcriptional regulation and 1 each in apoptosis, catabolism, cell adhesion, chromatin modification, folding protein, metabolism and response to stimulus, and 8 with unknown functions. Of the 16 genes underexpressed in larynx tumors, 2 were involved in cell cycle, 2 in DNA repair, and 1 each in apoptosis, biosynthesis, cell adhesion, immune response, protease inhibition, proteolysis, transcription regulation and transport, and 4 with unknown functions.
Interestingly, 6 of the 35 transcripts identified map to intronic regions of protein-coding genes (Table II) . While these partial transcripts may represent non-annotated exons of these genes, no significant open-reading frames and codingpotential was observed, as determined by the ESTScan software (31) , suggesting that these genes represent as yet uncharacterized non-coding RNAs that are deregulated in larynx tumors.
Validation of markers of larynx carcinoma by real-time RT-PCR. Quantitative real-time RT-PCR (qRT-PCR) was
employed to validate the larynx tumor gene expression by an independent method. We compared the relative expression levels of the 14 genes ADCY6, AES, ALS2CR3, CLK1, CRR9, CSTB, DUSP1, IL18BP, MAP3K5, PLAT, PTPRS, UBL1, XRCC5 and ZNF706 using triplicate measurements and normalization based on the ·-tubulin level. Data were analyzed using Student's t-test. Seven genes were statistically under- Figure 2 . Validation of the 35-gene classifier in an independent set of tumor and non-tumor larynx samples. Expression of the 35 genes identified in the training set was measured in an independent validation set comprised of 5 tumor and 6 non-tumor samples. Selected transcripts were grouped using hierarchical clustering (Wards method with half square Euclidean distance), and heat maps were constructed using the Spotfire software. For each gene (row), red indicates a higher expression and green a lower one, relative to the average level of expression of that gene across the 35 samples (columns). expressed in tumor samples compared to the normal reference, while three genes were statistically overexpressed. These data are summarized in Fig. 3 . The complete data with the relative expression levels detected by quantitative real-time PCR for the 14 genes in samples from larynx carcinoma are shown in Table IV .
We confirmed by qRT-PCR that genes ADCY6, AES, ALS2CR3, CSTB, DUSP1, MAP3K5 and PLAT are significantly down-regulated in tumor tissues compared to the normal reference (p=0.012, <0.0001, <0.0001, <0.0001, <0.0001, 0.014 and <0.0001, respectively). These genes, except ALS2CR3, are located in regions of chromosomal loss involved in head and neck carcinogenesis. The results of qRT-PCR were in agreement with those of the cDNA microarray analysis, further supporting evidence that these are potential cancer-related genes.
We found by qRT-PCR that genes CRR9, UBL1 and ZNF706 were significantly up-regulated in tumor tissues when compared to the normal reference (p=0.011, 0.007 and 0.001, respectively). It should be noted that these genes displayed expression patterns which were in contrast to the cDNA microarray analysis results. These genes are located in regions of chromosomal gains involved in head and neck carcinogenesis. The differential expression of CLK1, IL18BP, PTPRS and XRCC5 was not confirmed by qRT-PCR (p=0.406, 0.222, 0.083 and 0.340, respectively). Table IV . Natural logarithms of relative expression levels detected by quantitative real-time PCR for the 14 genes in samples from larynx carcinoma. 
----------------------------------------------------------------------------------------------------Gene Forward (F) and reverse (R) primers Amplicon size (bp) -----------------------------------------------------------------------------------------------------
ADCY6 F -5' -ACACCTGCTGACATCACTGC -3' 150 R -5' -GACAGAGCTGGCCAAGAGAC -3' AES F -5' -CCCAGCAACTCAAATTCACC -3' 116 R -5' -CTCACTGGCCAACTTGTCAC -3' ALS2CR3 F -5' -TTGCCTTCGAGGTTTTATGC -3' 108 R -5' -ATGGTTCCCAAGTTTGGTTG -3' TUBA1C F -5' -TCAACACCTTCTTCAGTGAAACG -3' 241 R -5' -AGTGCCAGTGCGAACTTCATC -3' CLK1 F -5' -AGGAGCATTTAGCAATGATG -3' 104 R -5' -CCAGTCTAATCGATCGTGGTG -3' CRR9 F -5' -TGGGTGCTGAGAACAACATC -3' 120 R -5' -ACAGCGTCCCATTGTTTCTC -3' CSTB F -5' -TGTCATTCAAGAGCCAGGTG -3' 100 R -5' -GGGAGAGATTGGAACACTCG -3' DUSP1 F -5' -GCGGAATCTGGGTGCAGTT -3' 81 R -5' -CAGGTACAGAAAGGGCAGGATTT -3' IL18BP F -5' -TAAGCAGTGTCCAGCATTGG -3' 83 R -5' -AGGCCACACAGGATAAGCTC -3' MAP3K5 F -5' -ACCGAAGAGAAGGGGAGAAG -3' 135 R -5' -CCGACCTGCGTAGACTATCC -3' PLAT F -5' -GAGTGCACCAACTGGAACAG -3' 125 R -5' -GGCTTTGAGTCTCGATCTGG -3' PTPRS F -5' -TCCTGCGAGAGTTCAAGGTC -3' 100 R -5' -GACTTTGGCACACCCTGTTC -3' UBL1 F -5' -TGACAACACATCTCAAGAAACTCAAA -3' 92 R -5' -TCTCTGACCCTCAAAGAGAAACCT -3' XRCC5 F -5' -ACCAAAGAGGAAGCCTCTGG -3' 121 R -5' -CGTCCACATCACCACCTTC -3' ZNF706 F -5' -AAATGCCAAAAAGCAAGCTG -3' 147 R -5' -TGCTTGCTCTCAAAGTGCTG -3' -----------------------------------------------------------------------------------------------------
a -------------------------------------------------------------------------------------------------------------------------------------------------

Gene -------------------------------------------------------------------------------------------------------------------------------------------------
ZNF706 -------------------------------------------------------------------------------------------------------------------------------------------------
T1
-0.58 
A pool of RNA isolated from 7 histologically normal larynx mucosa tissue samples adjacent to tumors were used as a reference. Experiments were performed in triplicate reactions and normalized for an endogenous control (·-tubulin). Statistical significance (P-value) was determined by one-sample Student's t-test as described in Materials and methods.
Discussion
The current literature includes several studies which included DNA microarray analysis in the study of HNSCC, to determine gene expression changes during disease progression and/or predict disease outcome. However, considerable heterogeneity among these studies exists in terms of study design, number of samples, sites and stage of disease, choice of microarray platform and validation of results by other laboratory methodologies (7). Many studies in HNSCC have been performed using tumors from various anatomical sites, but carcinomas from different upper aerodigestive tract sites may behave differently.Consequently, the results may be misleading when analyzed together. Larynx cancer is one of the most common types of HNSCC, with high mortality rates and poor prognosis (32) . Considering the above, our study examined, by microarray technology, the expression levels of 284 genes in clinical samples of larynx squamous cell carcinoma and nonneoplastic larynx tissue, identifying 35 genes as differentially regulated in tumor as compared to non-tumor tissue. The genes detected are primarily involved in processes such as apoptosis, cell cycle, DNA repair, proteolysis, protease inhibition, signal transduction and transcriptional regulation. Interestingly, six of the transcripts identified map to intronic regions of proteincoding genes. These sequences are unspliced and apparently have no coding potential. Long intronic non-coding RNAs (ncRNAs) are ubiquitously transcribed in the human genome (33, 34) and a subset of these ncRNAs were shown to correlate with the degree of tumor cell differentiation in prostate cancer (35) . We postulate that the intronic transcripts identified here comprise of as yet uncharacterized long ncRNAs that have a regulatory role in the gene expression program in larynx tissues and are deregulated in the neoplastic tissue.
Microarray data were further confirmed by real-time RT-PCR in a set of 14 genes which were found to be downregulated in tumor tissues by microarray analysis. Of the genes analyzed by microarray some showed similar patterns of expression by real-time RT-PCR. Thus, of the 14 selected genes tested by microarray and real-time RT-PCR, 7 showed congruent and significant down-regulation in tumor tissue, 3 displayed contrasting expression patterns with the two methods, while 4 did not exhibit any significant change in expression by real-time RT-PCR. One possible source of variation in the measurements of mRNA expression detected by microarray and real-time RT-PCR is the existence of different splicing isoforms, which may affect the transcript levels detected in different regions of the mRNA with these two techniques (36) . This result highlights the importance of performing independent real-time RT-PCR validation following the identification of candidates by high-throughput microarray screening before further conclusions on gene expression can be drawn (37) .
In the present study, 10 potential biomarkers of larynx carcinoma were validated and showed pronounced differences in expression between tumor and non-neoplastic samples. The validated markers were genes ADCY6, AES, AL2SCR3, CRR9, CSTB, DUSP1, MAP3K5, PLAT, UBL1 and ZNF706.
The expression of genes ADCY6, AES, ALS2CR3, CSTB, DUSP1, MAP3K5 and PLAT was significantly lower in tumor tissues than in the non-tumor adjacent tissue. Interestingly, these genes, except ALS2CR3, are located in regions of chromosomal loss involved in head and neck carcinogenesis.
Gene ADCY6, located at 12q14.1, encodes adenylate cyclase 6, which is a membrane-associated enzyme that catalyzes the formation of the secondary messenger cyclic adenosine monophosphate (cAMP). No information is available in the literature on ADCY6 expression in head and neck cancer. However, Celano et al (38) observed that its expression is significantly lower in hyperfunctioning thyroid tumors than in normal thyroid tissue, evidencing a low expression of this gene in transformed tissues.
The amino-terminal enhancer of the split (AES) gene, located at 19p13, encodes a 197-amino acid protein that is homologous to the NH(2)-terminal domain of the Drosophila Groucho protein but lacks COOH-terminal WD40 repeats. According to data of Tetsuka et al (39) , AES acts as a corepressor for NF-κß, which is well recognized as a regulator of genes encoding cytokines, chemokines and cell adhesion molecules important in immune and inflammatory responses, as well as critical genes in the control of cellular proliferation and apoptosis (40) .
Additionally, AES inhibits NF-κß,-dependent gene expression induced by tumor necrosis factor ·, interleukin-1 ß, and mitogen-activated protein kinase/extracellular signalregulated kinase kinase kinase 1, which is an upstream kinase for NF-κß activation (39) . There is evidence that nuclear factor NF-κß modulates a broad program of genes differentially expressed during tumor progression of HNSCC, such as CCND1 (PRADI), Gro-1 (IL-8 homologue) and GST (41) . Thus, the AES gene may play a role in head and neck carcinogenesis since it acts in the regulation of NF-κß and its target genes. Moreover, gene AES acts on the Wnt receptor signaling pathway. The nuclear output of Wnt signaling is mediated by a complex between DNA-binding proteins of the TCF family and the transcriptional coactivator ß-catenin. The Wnt/ß-catenin/Tcf pathway serves important functions in embryonic development and is constitutively activated in human colorectal cancer (42, 43) . Groucho proteins, which include AES, act to repress transcriptional activation by the ß-catenin-tcf complex, probably by interacting directly with Tcf transcriptional factors (42) . Thus, the low expression of the AES gene may contribute to a higher activation of the Wnt/ß-catenin/Tcf signaling model and consequently to larynx carcinogenesis, as occurs in colorectal cancer.
The ALS2CR3 gene, located at 2q33.1, is denominated as GRIF-1 and TRAK2. This gene encodes a factor that interacts with the Á-aminobutyric acid (A) receptor and plays a role in the intracellular transport, mainly in the kinesin-mediated transport of mitochondria (44) . Alterations of this gene have been associated with neurodegenerative diseases (45) . Currently, however, no studies are available in the literature describing alterations of ALS2CR3 in tumor tissues.
Cystatin B, also called stefin B, is a small protein that is a member of the superfamily of cysteine protease inhibitors. Cystatins have emerged as important players in a multitude of physiological and pathophysiological settings that range from cell survival and proliferation to differentiation, cell signaling and immunomodulation (46) . Cysteine proteases, ONCOLOGY REPORTS 21: 649-663, 2009 in turn, have been implicated in multiple steps of tumor progression, including early steps of immortalization and transformation (47) , intermediate steps of tumor invasion and angiogenesis (48) , and late steps of metastasis and drug resistance (49) . The importance of lysosomal cysteine proteases in the progression of tumors from benign to aggressive lesions suggests that cystatins in many ways safeguard against tumor progression (46) .
In a review on gene expression profiles, a low expression of the CSTB (cystatin B) gene, located at 21q22.3, was reported in 5 of 24 HNSCC microarray studies (7) . A decrease of CSTB expression was observed in esophageal carcinoma, breast cancer, prostatic adenocarcinomas and atypical meningiomas (50) (51) (52) (53) .
The DUSP1 gene, also referred to as MSP-1 and located at 5q35.1, encodes a dual-specificity phosphatase for tyrosine and threonin (54) . This gene specifically inactivates mitogenactivated protein kinase and suppresses its activation by ras. The DUSP1 gene is also a transcriptional target of tumor suppressor p53, inducing cell cycle arrest or apoptosis. Consequently, DUSP1 may play an important role in the negative regulation of cell proliferation (54, 55) .
A low expression of DUSP1 has been observed in ovarian and prostate cancer (56, 57) . Moreover, in line with our study, Tomioka et al (58) observed a low expression of this gene in head and neck cancer. These authors considered DUSP1 a candidate for tumor suppression, mediating PTEN signaling pathways. Unoki and Nakamura (59) reported that DUSP1 gene expression was induced by the introduction of exogenous PTEN into endometrial cancer cell lines.
In addition, DUSP1 plays a vital role in the regulation of innate immune responses via the p38 MAPK and JNK pathways and appears to play a role in the induction of senescence through the inhibition of AP-1 activity and the subsequent transcription of genes involved in DNA replication (60, 61) .
Gene MAP3K5, located at 6q25.1 and denominated as apoptosis signal-regulating kinase 1 (ASK1), encodes a multifunctional serine/threonine kinase involved in a broad range of biological activities including cell differentiation and stressinduced apoptosis (62, 63) . Its catalytic activity can be activated by many stress stimuli such as tumor necrosis factor · (TNF-·), reactive oxygen species (ROS), DNA damage and chemotherapeutic agents such as cisplatin and taxol, and selectively activates JNK and p38 MAPK pathways (64) .
The pro-apoptotic role of MAP3K5 is reinforced by Dasgupta et al (65) and Kherrouche et al (66) . Dasgupta et al (65) described a physical and functional interaction between MAP3K5 and the Rb protein in response to apoptotic stimuli. The Rb protein has antiproliferative and antiapoptotic functions. It appears that MAP3K5 has to overcome RB functions to induce apoptosis. Moreover, the MAP3K5-mediated inactivation of Rb correlates with increased levels of the pro-apoptotic protein p73. Kherrouche et al (66) suggest that the overexpression of E2F1 induces the expression of MAP3K5 and that some of the cellular functions of MAP3K5 are under the control of the E2F transcriptional factor. The authors also suggest that the up-regulation of MAP3K5 favor the p53-independent E2F1 apoptotic activity. However, no information is available in the literature regarding MAP3K5 expression in head and neck cancer.
The PLAT gene, located at 8p11.21, encodes the tissuetype plasminogen activator, a secreted serine protease which converts the proenzyme plasminogen to plasmin, a fibrinolytic enzyme (67) . Numerous studies have provided evidence that plasminogen activators (PA)/plasmin systems represent a key event in angiogenesis. It is well established that tumorinduced neovascularization and angiogenesis are necessary requirements for the growth of tumors and their metastases. The PA/plasmin system comprises two major types of PA, tissue (PLAT) and urokinase (PLAU) (68) .
In contrast to PLAU, for which considerable evidence indicates that up-regulation of the enzyme correlates with tumor aggression, several observations suggest that high PLAT levels correlate with good prognosis in melanoma and breast cancer, whereas lower PLAT levels have been associated with malignant tumors (69, 70) . These findings suggest that an increase in either PLAT activity or expression levels is beneficial, possibly due to the overstimulation of plasmin generation by PLAT that induces the degradation of the pro-angiogenic fibrin matrix, resulting in the inhibition of angiogenesis (71, 72) . Moreover, Gingras et al (72, 73) reported that Neovastat, an inhibitor of angiogenesis derived from marine cartilage, specifically stimulates PLAT-dependent plasmin generation through an increase in the affinity of the enzyme towards plasminogen.
Expression of the CRR9, UBL1 and ZNF706 genes was significantly higher in tumor tissues than in the normal reference. These genes are located in regions of chromosomal gains involved in head and neck carcinogenesis.
The CRR9 gene, located at 5pter15.33, has an unknown function. A high expression of this gene was observed in a renal carcinoma cell line when compared to normal cells, as well as in a cell line of ovary cancer resistant to treatment with cisplatin (74, 75) . However, no information is available in the literature on CRR9 expression in head and neck cancer.
The UBL1 gene, also referred to as SUMO-1 and located at 2q33.1, is likely to be involved in many cellular processes, including apoptosis, mitosis regulation, protein translocation, cell proliferation and transcriptional regulation. One function of the UBL1 protein is to conjugate covalently with target proteins and modify their function. Consequently, in the nucleus, the transcriptional activities of UBL1-modified transcriptional factors including p53, c-jun, Sp-3, c-Myc and c/EBP families are reduced (76, 77) .
The UBL1 protein forms a complex with RAD51 and RAD52 proteins in human cells, which play essential roles in DNA homologous recombination, DNA repair and cell proliferation. UBL1 overexpression down-regulates DNA double-strand break-induced homologous recombination in CHO cells and reduces cellular resistance to ionizing radiation. Overexpression of UBL1 reduces the fraction of bidirectional gene conversion tracts, and that of a mutant UBL1 that is incapable of being conjugated retains the ability to inhibit homologous recombination (78) . These results suggest a regulatory role for UBL1 in homologous recombination.
The UBL1 protein was found to repress MAPK5 activation through physical interaction (79) . Therefore, UBL1 overexpression may contribute to carcinogenesis by decreasing DNA repair capacity and inhibiting MAP3K5 activation and, consequently, apoptosis. Currently, no information is available in the literature on UBL1 expression in head and neck cancer. However, a high UBL1 expression was observed in a renal carcinoma cell line when compared to normal cells (80) .
No information is available in the literature on ZNF706 expression in cancer. The zinc finger gene family belongs to one of the largest families of transcriptional factors. Most zinc finger proteins bind to specific DNA sequences and are involved in the transcriptional regulation of gene expression. Members of the zinc finger family function as activators or repressors of gene transcription, regulating embryonic development as well as a variety of physiological processes in the adult (81) . Zinc-finger-containing transcriptional factors have previously been involved in MAPK signaling pathway regulation. These factors are among the most widespread mechanisms of eukaryotic cell regulation (82) .
According to the holistic model of cancer proposed by Hanahan and Weinberg (83), a malignant cell has to acquire 6 biological alterations to dictate pathogenesis: self-sufficiency in proliferative growth signals, insensitivity to growth inhibitor signals, evasion of apoptosis, limitless replication potential, sustained angiogenesis and the induction of invasion. By verifying this model, our study shows a set of differentially expressed genes, especially AES, CSTB, DUSP1, MAP3K5, PLAT and UBL1 that can directly or indirectly feed these pathways.
Among the differentially expressed genes, we emphasize CSTB. Notably, this gene showed a low expression in the tumor samples analyzed by microarray and real-time RT-PCR. The CSTB gene has an antimetastatic function, since it inhibits lysosomal cysteine protease action. Despite mounting evidence showing that the expression of lysosomal cysteine proteases is aberrant in tumor versus normal cells, this class of proteases has yet to be investigated (46) . Emphasis has been placed on metalloproteases as potential novel targets for anti-cancer chemotherapy. Clinical trials with cancer patients have provided no indication that metalloprotease inhibitors are successful (84) . This has led to a growing interest in members of the cystatin superfamily for potential novel anticancer strategies, and pre-clinical studies are promising (85) . Several clinical studies have shown that some cathepsins and/or cystatins may have diagnostic and/or prognostic value in a variety of cancer types (52, 53, 86) Since loco-regional relapse and metastasis appear to be significant contributing factors for the restricted survival of HNSCC patients (1), we suggest that the CSTB gene constitutes a good biomarker for larynx cancer and deserves more attention in future studies.
In conclusion, our microarray analysis revealed a gene expression signature of larynx tumors, including several genes whose deregulation is potentially associated with disease progression. Further studies are required to evaluate whether the genes identified in this study are specifically altered in larynx tumors or are deregulated in other head and neck tumors. These findings will contribute to the understanding of the molecular basis of larynx cancer, thus helping to improve diagnosis, treatment and patient outcome.
